SCP
ZNTL icon

Sivia Capital Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sivia Capital Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.8K Hold
20,000
– – 0.01% 451
2025
Q4 		$27K Buy
+20,000
New +$29.1K 0.01% 553

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Sivia Capital Partners's ZNTL Position: Q1 2026 in Review

Sivia Capital Partners held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 20,000 shares worth $46.8K. The position accounts for 0.01% of the portfolio, ranked #451.

Sivia Capital Partners first reported a position in ZNTL in Q4 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Sivia Capital Partners held 20,000 shares of Zentalis Pharmaceuticals worth $46.8K as of Q1 2026.
  • Sivia Capital Partners left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
  • Zentalis Pharmaceuticals made up 0.01% of Sivia Capital Partners's portfolio in Q1 2026, its #451 holding.
  • Sivia Capital Partners first reported a position in Zentalis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Sivia Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.